Diya Surie
YOU?
Author Swipe
View article: Effectiveness of 2024–2025 COVID-19 Vaccination Against COVID-19 Hospitalization and Severe In-Hospital Outcomes — IVY Network, 26 Hospitals, September 1, 2024–April 30, 2025
Effectiveness of 2024–2025 COVID-19 Vaccination Against COVID-19 Hospitalization and Severe In-Hospital Outcomes — IVY Network, 26 Hospitals, September 1, 2024–April 30, 2025 Open
Importance As SARS-CoV-2 JN.1 lineage descendants continue to evolve, evaluating COVID-19 vaccine effectiveness (VE) against severe COVID-19 is necessary to inform vaccine composition updates. Objective To estimate effectiveness of 2024–20…
View article: Incidence Rates of RSV‐Associated Hospitalizations Among Adults in Middle Tennessee, United States, October 2022 Through September 2023
Incidence Rates of RSV‐Associated Hospitalizations Among Adults in Middle Tennessee, United States, October 2022 Through September 2023 Open
We estimated the burden of RSV‐associated hospitalizations in US adults 1 year prior to RSV vaccine introduction. The overall annual incidence rate of RSV‐associated hospitalization was 31.47 (95% CI: 21.89–43.97) per 100,000 adults. Rates…
View article: Integrating genomic data into test-negative designs for estimating lineage-specific COVID-19 vaccine effectiveness
Integrating genomic data into test-negative designs for estimating lineage-specific COVID-19 vaccine effectiveness Open
Background SARS-CoV-2 lineage-specific vaccine effectiveness (VE) studies can inform decision-making on whether COVID-19 vaccine composition updates are needed to maintain effectiveness against severe disease as SARS-CoV-2 continues to evo…
View article: Bridging the digital divide: Understanding COVID-19 diagnostic and vaccination experiences in a socioeconomically disadvantaged neighborhood in Sweden
Bridging the digital divide: Understanding COVID-19 diagnostic and vaccination experiences in a socioeconomically disadvantaged neighborhood in Sweden Open
BACKGROUND: The COVID-19 pandemic had a significant impact on the public health and the economy of the Swedish population, with disproportionate effects on communities living in socioeconomically diverse neighborhoods. To mitigate these im…
View article: Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults with Respiratory Syncytial Virus
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults with Respiratory Syncytial Virus Open
Background Adults hospitalized with acute respiratory infections, including respiratory syncytial virus (RSV), often have multiple underlying conditions. Few data are available on the combined effect of conditions on risk of severe outcome…
View article: Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination
Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination Open
Importance In 2023, the first respiratory syncytial virus (RSV) vaccines were recommended for US adults 60 years or older, but few data are available about which patients were most likely to receive vaccine to inform future RSV vaccine out…
View article: Genomic Characterization of RSV in the US by Vaccination Status
Genomic Characterization of RSV in the US by Vaccination Status Open
This study examines respiratory syncytial virus (RSV) genomic surveillance results from 2 large US networks after the introduction of RSV vaccines.
View article: In Vitro Study Comparing SARS-CoV-2 Ancestral and Omicron Lineages Sequence & Neutralization Differences
In Vitro Study Comparing SARS-CoV-2 Ancestral and Omicron Lineages Sequence & Neutralization Differences Open
Introduction: COVID-19 remains a worldwide public health concern. SARS-CoV-2 binds to cells via its spike (S) protein, which has undergone significant evolution since its emergence. New SARS-CoV-2 variants can differentially escape antibod…
View article: Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness — Four Vaccine Effectiveness Networks, United States, October 2024–February 2025
Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness — Four Vaccine Effectiveness Networks, United States, October 2024–February 2025 Open
Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hos…
View article: Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025
Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025 Open
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2…
View article: P-2069. Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against COVID-19–associated Hospitalization Among Adults — IVY Network, 20 U.S. States
P-2069. Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against COVID-19–associated Hospitalization Among Adults — IVY Network, 20 U.S. States Open
Background On September 12, 2023, the Advisory Committee on Immunization Practices recommended updated 2023–2024 (Monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19. Few data are available on the ef…
View article: Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study
Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study Open
Background Clinical guidelines recommend initiation of antiviral therapy as soon as possible for patients hospitalized with confirmed or suspected influenza. Methods A multicenter US observational sentinel surveillance network prospectivel…
View article: Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023 Open
Background Assessments of COVID‐19 vaccine effectiveness are needed to monitor the protection provided by updated vaccines against severe COVID‐19. We evaluated the effectiveness of original monovalent and bivalent (ancestral strain and Om…
View article: RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older
RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older Open
This study evaluates the effectiveness of the respiratory syncytial virus vaccine against hospitalization for acute respiratory illness among US adults aged 60 years and older.
View article: Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024 Open
Background Assessing variant-specific coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) and severity can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.…
View article: Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024 Open
Background Assessing COVID-19 vaccine effectiveness (VE) and severity of SARS-CoV-2 variants can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collec…
View article: Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves
Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into numerous lineages with unique spike mutations and caused multiple epidemics domestically and globally. Although COVID-19 vaccines are available, new variants wit…
View article: Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults Open
Importance On June 21, 2023, the Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccines for adults aged 60 years and older using shared clinical decision-making. Understanding the severi…
View article: Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States Open
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patien…
View article: Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024 Open
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estima…
View article: SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis
SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis Open
View article: Durability of protection from original monovalent and bivalent COVID-19 vaccines against COVID-19-associated hospitalization and severe in-hospital outcomes among adults in the United States — September 2022–August 2023
Durability of protection from original monovalent and bivalent COVID-19 vaccines against COVID-19-associated hospitalization and severe in-hospital outcomes among adults in the United States — September 2022–August 2023 Open
Objective To evaluate the durability of protection provided by original monovalent and bivalent COVID-19 vaccination against COVID-19-associated hospitalization and severe in-hospital outcomes. Design Multicenter case-control design with p…
View article: Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013–2020
Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013–2020 Open
India has the largest number of multidrug-resistant TB (MDR-TB) cases, defined as Mycobacterium tuberculosis resistant to at least isoniazid (INH) and rifampicin (RIF).1 However, less than half of all persons with MDR-TB in India successfu…
View article: Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023
Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023 Open
Background Influenza circulation during the 2022–2023 season in the United States largely returned to pre–coronavirus disease 2019 (COVID-19)-pandemic patterns and levels. Influenza A(H3N2) viruses were detected most frequently this season…
View article: 1097. A Prospective Evaluation of <i>SARS-CoV-2</i> Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023
1097. A Prospective Evaluation of <i>SARS-CoV-2</i> Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023 Open
Background Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict or source the emergence of highly mutated variants of concern. The types of immunosuppression placing patients at highest risk for prolonged infection and as…
View article: 1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023
1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023 Open
Background Data on the severity of RSV-associated hospitalizations in adults compared with COVID-19- and influenza-associated hospitalizations are limited. We compared characteristics and clinical outcomes among adults hospitalized with RS…
View article: 2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023
2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023 Open
Background On September 1, 2022, the Advisory Committee on Immunization Practices recommended a bivalent mRNA COVID-19 booster dose for persons who had completed at least a primary COVID-19 vaccination series ≥2 months earlier. Early data …
View article: Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023
Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023 Open
On June 21, 2023, CDC's Advisory Committee on Immunization Practices recommended respiratory syncytial virus (RSV) vaccination for adults aged ≥60 years, offered to individual adults using shared clinical decision-making. Informed use of t…
View article: SARS-CoV-2 shedding and evolution in immunocompromised hosts during the Omicron period: a multicenter prospective analysis
SARS-CoV-2 shedding and evolution in immunocompromised hosts during the Omicron period: a multicenter prospective analysis Open
Background Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict or source the emergence of highly mutated variants. The types of immunosuppression placing patients at highest risk for prolonged infection and associated in…
View article: High-level Colonization With Antibiotic-Resistant Enterobacterales Among Individuals in a Semi-Urban Setting in South India: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study
High-level Colonization With Antibiotic-Resistant Enterobacterales Among Individuals in a Semi-Urban Setting in South India: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study Open
Background Antimicrobial resistance poses a significant threat to public health globally. We studied the prevalence of colonization with extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE), carbapenem-resistant Enterobactera…